Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer - Concepedia

Concepedia

Publication | Open Access

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

DOI Full Paper Access

88

Citations

28

References

2020

Year

Michael J. Overman, Milind Javle, R. Eric Davis, Pankaj Vats, Chandan Kumar‐Sinha, Lianchun Xiao, Niharika B. Mettu, Edwin R. Parra, Al B. Benson, Charles D. Lopez,

Journal for ImmunoTherapy of Cancer

Abstract

NCT02362048.

References

	Year	Citations

Page 1